Европейски съюз - естонски - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastilised ained - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Европейски съюз - естонски - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lümfoom, mantle-cell - antineoplastilised ained - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Естония - естонски - Ravimiamet

medochemie limited - vorikonasool - infusioonilahuse pulber - 200mg 1tk

Европейски съюз - естонски - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mitu müeloomit - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Европейски съюз - естонски - EMA (European Medicines Agency)

instituto grifols, s.a. - inimese fibrinogeen, inimese trombiin - hemostaas, kirurgiline - antihemorraagilised ained - toetav ravi täiskasvanutel, kui standard operatsiooni-tehnika ei piisa:et parandada haemostasisas õmblusmaterjalid toetust, kardiovaskulaarkirurgia.

Естония - естонски - Ravimiamet

teva pharma b.v. - vorikonasool - õhukese polümeerikattega tablett - 200mg 30tk; 200mg 20tk; 200mg 2tk; 200mg 28tk; 200mg 98tk; 200mg 50tk; 200mg 56tk; 200mg 14tk; 200mg 10tk

Естония - естонски - Ravimiamet

medochemie limited - vorikonasool - õhukese polümeerikattega tablett - 50mg 50tk; 50mg 14tk; 50mg 28tk; 50mg 2tk; 50mg 30tk; 50mg 20tk; 50mg 56tk; 50mg 100tk

Естония - естонски - Ravimiamet

medochemie limited - vorikonasool - õhukese polümeerikattega tablett - 200mg 10tk; 200mg 30tk; 200mg 50tk; 200mg 56tk; 200mg 28tk; 200mg 20tk; 200mg 100tk

Естония - естонски - Ravimiamet

sandoz pharmaceuticals d.d. - vorikonasool - õhukese polümeerikattega tablett - 200mg 30tk; 200mg 1000tk; 200mg 10tk; 200mg 14tk; 200mg 56tk; 200mg 20tk; 200mg 50tk; 200mg 98tk; 200mg 60tk

Естония - естонски - Ravimiamet

sandoz pharmaceuticals d.d. - vorikonasool - õhukese polümeerikattega tablett - 50mg 56tk; 50mg 500tk; 50mg 28tk; 50mg 98tk; 50mg 2tk; 50mg 14tk; 50mg 100tk; 50mg 1000tk; 50mg 10tk